Skip to Main Content

Sawai News

Notice of Change in Representative Directors

Osaka, Japan – March 23, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) decided, at the Board of Directors’ meeting held today, to implement changes in Representative Director. The ...
Read More

Sawai Launches Tadalafil Tablets

Osaka, Japan – March 6, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) announced the launch dates with the below-mentioned schedule for Tadalafil tablets (the branded product: Cialis®). Tadalafil tablets ...
Read More

Sawai Receives Approval for Tadalafil Tablets

Osaka, Japan – February 19, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Tadalafil tablets (the branded ...
Read More

Sawai Receives Approvals for Two Generic Drugs with Five Strengths

Osaka, Japan – August 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for two generic drugs with five strengths. The two compounds, Aprepitant and Micafungin Sodium are approved for the first time ...
Read More